For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues | 0 | 0 | - | 8 |
| Cost of revenues | 0 | 0 | - | 3.2 |
| Gross profit | 0 | 0 | - | 4.8 |
| Research and development | 465.154 | 501.261 | 581.796 | 924.749 |
| Selling, general and administrative | 776.821 | 731.517 | 498.607 | 676.086 |
| Amortization of patent costs | 31.059 | 30.742 | 29.271 | 29.271 |
| Total expenses | 1,273.034 | 1,263.52 | 1,109.674 | 1,630.106 |
| Operating loss | -1,273.034 | -1,263.52 | -1,109.674 | -1,625.306 |
| Interest income | 37.1 | 30.217 | 69.539 | 67.578 |
| Total other income (expense) | 37.1 | 30.217 | 69.539 | 67.578 |
| Loss before provision for income taxes | -1,235.934 | -1,233.303 | -1,040.135 | -1,557.728 |
| Provision for income taxes | 0 | 0 | - | - |
| Net loss | -1,235.934 | -1,233.303 | -1,040.135 | -1,557.728 |
| Diluted EPS | -0.48 | -0.48 | - | - |
| Diluted Average Shares | 2,580,532 | 2,580,532 | - | - |
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)